Eli Lilly pauses India obesity campaign after regulator warning and seeks clearer promotion rules

The regulator flagged indirect promotion despite no product names

Eli Lilly has paused its obesity awareness campaign in India after the country’s drug regulator cautioned it over potential rule violations. The initiative sought to reframe obesity as a chronic disease using multiple media formats without naming specific products. Lilly says regulatory uncertainty and conflicting guidance led to the halt, while the regulator warned against indirect promotion of medicines.